Clinical Trial Update: Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors [Phase 2]

View source ↗

Summary

A Phase II trial evaluating trastuzumab plus paclitaxel for HER2-positive locally advanced breast cancer and epirubicin plus docetaxel for HER2-negative tumors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• HERCEPTIN (trastuzumab)
• Taxol (paclitaxel)
• Taxotere (docetaxel)

Snippet

Sponsor: Centro di Riferimento Oncologico - Aviano | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED